Search: (WFRF:(Bhatt Deepak L)) srt2:(2015-2019) >
Renal Function and ...
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI
-
- Hohnloser, Stefan H. (author)
- Goethe Univ Frankfurt, Dept Cardiol, Theodor Stern Kai 7,Bldg 23A, D-60590 Frankfurt, Germany
-
- Steg, Philippe Gabriel (author)
- Hop Bichat Claude Bernard, FACT, Dept Hosp Univ, Paris, France;Univ Paris Diderot, Paris, France;INSERM, U1148, Paris, France;Hop Bichat Claude Bernard, AP HP, Paris, France
-
- Oldgren, Jonas, 1964- (author)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
show more...
-
- Nickenig, Georg (author)
- Univ Bonn, Med Klin & Poliklin 2, Bonn, Germany
-
- Kiss, Robert G. (author)
- Hungarian Def Forces, Med Ctr, Budapest, Hungary
-
- Ongen, Zeki (author)
- Istanbul Univ Cerrahpasa, Dept Cardiol, Istanbul, Turkey
-
- Navarro Estrada, Jose L. (author)
- Hosp Italiano Buenos Aires, Dept Cardiol, Buenos Aires, DF, Argentina
-
- Ophuis, Ton Oude (author)
- Canisius Wilhelmina Hosp, Dept Cardiol, Nijmegen, Netherlands
-
- Lip, Gregory Y. H. (author)
- Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England;Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England;Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
-
- Nordaby, Matias (author)
- Boehringer Ingelheim Int GmbH, Ingelheim, Germany
-
- Kleine, Eva (author)
- Boehringer Ingelheim Int GmbH, Ingelheim, Germany
-
- ten Berg, Jurrien M. (author)
- St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands
-
- Bhatt, Deepak L. (author)
- Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA;Harvard Med Sch, Boston, MA 02115 USA
-
- Cannon, Christopher P. (author)
- Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA;Harvard Med Sch, Boston, MA 02115 USA
-
show less...
-
(creator_code:org_t)
- ELSEVIER SCIENCE INC, 2019
- 2019
- English.
-
In: JACC. - : ELSEVIER SCIENCE INC. - 1936-8798 .- 1876-7605. ; 12:16, s. 1553-1561
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVES: The study sought to evaluate the effect of dabigatran dual therapy versus warfarin triple therapy across categories of renal function in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.BACKGROUND: The RE-DUAL PCI (NCT02164864) trial of patients with atrial fibrillation undergoing percutaneous coronary intervention reported that dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) reduced the primary endpoint of major bleeding events (MBE) or clinically relevant nonmajor bleeding events (CRNMBE) compared with warfarin triple therapy, with noninferiority in overall thromboembolic events.METHODS: Risk of a first MBE or CRNMBE and the composite of death or thromboembolic event (DTE) or unplanned revascularization were evaluated in 2,725 patients according to baseline creatinine clearance (CrCl) categories: 30 to <50, 50 to <80, and >= 80 ml/min.RESULTS: Compared with warfarin, dabigatran 110 mg dual therapy reduced risk of MBE or CRNMBE across all categories of CrCl (p for interaction = 0.19). Dabigatran 150 mg dual therapy reduced risk of MBE or CRNMBE regardless of the CrCl category (p for interaction = 0.31). Risk of DTE or unplanned revascularization was similar to warfarin triple therapy for dabigatran 110 mg dual therapy across all CrCl categories. Dabigatran 150 mg dual therapy versus warfarin triple therapy had similar risk for DTE or unplanned revascularization in patients with CrCl 30 to <80 ml/min and lower risk at CrCl >= 80 ml/min (p for interaction = 0.02).CONCLUSIONS: In the RE-DUAL PCI trial, dabigatran dual therapy reduced bleeding events versus warfarin triple therapy irrespective of renal function, with overall similar risks of thromboembolic events but lower risks with dabigatran 150 mg in patients with normal CrCl.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- atrial fibrillation
- dabigatran dual therapy
- percutaneous coronary intervention
- renal function
- warfarin triple therapy
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
JACC
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Hohnloser, Stefa ...
-
Steg, Philippe G ...
-
Oldgren, Jonas, ...
-
Nickenig, Georg
-
Kiss, Robert G.
-
Ongen, Zeki
-
show more...
-
Navarro Estrada, ...
-
Ophuis, Ton Oude
-
Lip, Gregory Y. ...
-
Nordaby, Matias
-
Kleine, Eva
-
ten Berg, Jurrie ...
-
Bhatt, Deepak L.
-
Cannon, Christop ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
JACC
- By the university
-
Uppsala University